CoChat
Sign Up
Cited by 54

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

L-ornithine L-aspartate for prevention and treatment of hepatic encephalopathy in people with cirrhosis

Goh, Ee Teng, Stokes, Caroline S, Sidhu, Sandeep S, Vilstrup, Hendrik, Gluud, Lise Lotte, Morgan, Marsha Y·2018·Cochrane Database of Systematic Reviews
DOI 10.1002/14651858.cd012410.pub2
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/14651858.cd012410.pub2

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Show all 5 references

Research works printed but not linked: 128

  1. Abid, 2011, Efficacy of L-ornithine-L-aspartate as an adjuvant therapy in cirrhotic patients with hepatic encephalopathy, Journal of the College of Physicians and Surgeons Pakistan, 21, 666
  2. Abid, 2005, Efficacy of infusion of L-ornithine L-aspartate in cirrhotic patients with portosystemic encephalopathy: a placebo controlled study [abstract], Journal of Hepatology, 42, 84
  3. Ahmad, 2008, L-ornithine-L-aspartate infusion efficacy in hepatic encephalopathy, Journal of the College of Physicians and Surgeons Pakistan, 18, 684
  4. Alvares-da-Silva, 2011, Oral L-ornithine L-aspartate (LOLA) in cirrhotic patients with minimal hepatic encephalopathy (MHE): final results of a randomized double-blind placebo-controlled trial (PORTO ALEGRE STUDY) [abstract], Hepatology (Baltimore, Md.), 54, 1249A
  5. Alvares-da-Silva, 2014, Oral L-ornithine-L-aspartate in minimal hepatic encephalopathy: a randomized, double-blind, placebo-controlled trial, Hepatology Research, 44, 956, 10.1111/hepr.12235 · DOI
  6. Bai M He C Yin Z Niu J Wang Z Qi X Randomised clinical trial: L-ornithine-l-aspartate reduces significantly the increase of venous ammonia concentration after TIPSS Alimentary Pharmacology & Therapeutics 2014 63 71 dx.doi.org/10.1111/apt.12795 · DOI
  7. Blanco Vela, 2011, L-ornithine L-aspartate is as effective as nonabsorbable disaccharides in the management of acute hepatic encephalopathy [abstract], Hepatology (Baltimore, Md.), 54, 1899
  8. Chen, 2005, Therapeutic effect of L-ornithine-L-aspartate on liver cirrhosis complicated by hepatic encephalopathy, Di Yi Jun Yi Da Xue Xue Bao, 25, 718
  9. Feher, 1997, Effect of ornithine-aspartate infusion on elevated serum ammonia concentration in cirrhotic patients - results of a randomized, placebo-controlled double-blind multicentre trial, Medical Science Monitor, 3, 669
  10. Fleig, 1999, Placebo-controlled, double-blind evaluation of L-ornithine–L-aspartate (LOLA) granules in patients with cirrhosis and subclinical (SHE) or mild overt hepatic encephalopathy (HE) [abstract], Journal of Hepatology, 30, 65
  11. Kircheis, 2007, Assessment of low-grade hepatic encephalopathy: a critical analysis, Journal of Hepatology, 47, 642, 10.1016/j.jhep.2007.05.019 · DOI
  12. Hasan I Iskandar M Budihusodo U Effect of L-ornithine-L-aspartate on liver cirrhosis patients with low-grade hepatic encephalopathy [abstract] Hepatology International 2012 295 dx.doi.org/10.1007/s12072-011-9333-4 · DOI
  13. Higuera-de la Tijera, 2017, A randomized, double-blind, clinical trial comparing lactulose, L-ornithine L-aspartate, or rifaximin, versus placebo, as primary prophylaxis of hepatic encephalopathy in cirrhotic patients with variceal bleeding, Journal of Hepatology, 66, S49, 10.1016/S0168-8278(17)30362-8 · DOI
  14. Hong, 2003, Clinical control study of L-ornithine-L-aspartate in the treatment of subclinical hepatic encephalopathy, West China Medical Journal, 4, 508
  15. Kircheis, 1997, Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study, Hepatology (Baltimore, Md.), 25, 1351, 10.1002/hep.510250609 · DOI
  16. Kircheis, 1997, Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study [abstract], Hepatology Research, 8, 221
  17. Maldonado, 2010, Clinical efficacy of L-ornithine L-aspartate in the prevention of altered oral glutamine challenge in patients with minimal hepatic encephalopathy: a pilot study [abstract], Gastroenterology, 138, S818
  18. Delcker, 2000, L-ornithine-L-aspartine vs placebo in the treatment of hepatitis encephalopathy: meta-analysis of randomised placebo-controlled trials using individual data (MRZ 90004-8806), Hepatology (Baltimore, Md.), 32, 310A
  19. Delcker, 2000, L-ornithine-L-aspartine vs placebo in the treatment of hepatitis encephalopathy: meta-analysis of randomised placebo-controlled trials using individual data (MRZ 90004-8807), Hepatology (Baltimore, Md.), 32, 310A
  20. Delcker, 2000, L-ornithine-L-aspartine vs placebo in the treatment of hepatitis encephalopathy: meta-analysis of randomised placebo-controlled trials using individual data (MRZ 90004-8901), Hepatology (Baltimore, Md.), 32, 310A
  21. Mittal, 2011, A randomized controlled trial comparing lactulose, probiotics, and L-ornithine L-aspartate in treatment of minimal hepatic encephalopathy, European Journal of Gastroenterology and Hepatology, 23, 725, 10.1097/MEG.0b013e32834696f5 · DOI
  22. Ndraha, 2011, The effect of L-ornithine L-aspartate and branch chain amino acids on encephalopathy and nutritional status in liver cirrhosis with malnutrition, Acta Medica Indonesiana, 43, 18
  23. Nimanong, 2010, Oral L-ornithine-L-aspartate (LOLA) for patients with overt hepatic encephalopathy treated with lactulose; a randomized, double-blinded, placebo-controlled trial [abstract], Hepatology International, 4, 35
  24. Nimanong, 2010, Oral L-ornithine-L-aspartate (LOLA) for patients with overt hepatic encephalopathy treated with lactulose; a randomized, double-blinded, placebo-controlled trial [abstract], Journal of Hepatology, 52, S78, 10.1016/S0168-8278(10)60182-1 · DOI
  25. Oruc, 2010, Therapeutic efficacy of L-ornithine-L-aspartate infusions in patents with cirrhosis and hepatic encephalopathy [abstract], Journal of Hepatology, 52, S78, 10.1016/S0168-8278(10)60184-5 · DOI
  26. Poo, 2006, Efficacy of oral L-ornithine-L-aspartate in cirrhotic patients with hyperammonemic hepatic encephalopathy. Results of a randomized, lactulose-controlled study, Annals of Hepatology, 5, 281, 10.1016/S1665-2681(19)31989-1 · DOI
  27. Poo, 2007, Efficacy and safety of L-ornithine L-aspartate (LOLA) administration. Open label randomized controlled trial versus lactulose in cirrhotic patients with hyperammoniemic hepatic encephalopathy [abstract], Journal of Hepatology, 46, S36, 10.1016/S0168-8278(07)61679-1 · DOI
  28. Puri, 2010, Treatment of minimal hepatic encephalopathy: a randomized control trial comparing L ornithine L aspartate with placebo [abstract], Indian Journal of Gastroenterology, 29, 65
  29. Schmid, 2008, Prospective randomized pilot trial of I.V. L-ornithine L-aspartate vs. placebo on postural control in patients with cirrhosis [abstract], Journal of Hepatology, 48, S123, 10.1016/S0168-8278(08)60312-8 · DOI
  30. Schmid, 2010, A double-blind, randomized, placebo-controlled trial of intravenous L-ornithine-L-aspartate on postural control in patients with cirrhosis, Liver International, 30, 574, 10.1111/j.1478-3231.2010.02213.x · DOI · Paper page
  31. Sharma, 2012, Minimal hepatic encephalopathy: effect of rifaximin, probiotics and L-ornithine L-aspartate, Journal of Gastroenterology and Hepatology, 27, 275
  32. Sharma, 2014, Effect of rifaximin, probiotics, and L-ornithine L-aspartate on minimal hepatic encephalopathy: a randomized controlled trial, Saudi Journal of Gastroenterology, 20, 225, 10.4103/1319-3767.136975 · DOI
  33. Sidhu SS Sharma BC Goyal O Kishore H Kaur N L-ornithine L-aspartate in bouts of overt hepatic encephalopathy Hepatology (Baltimore, Md.) 2018 700 10 10.1002/hep.29410 · DOI · Paper page
  34. Stauch, 1998, Oral L-ornithine-L-aspartate therapy of chronic hepatic encephalopathy: results of a placebo-controlled double-blind study, Journal of Hepatology, 28, 856, 10.1016/S0168-8278(98)80237-7 · DOI
  35. Pasha, 2017, Brain muscle axis during treatment of hepatic encephalopathy with L-ornithine L-aspartate, Journal of Clinical and Experimental Hepatology, 7, S5, 10.1016/j.jceh.2017.01.009 · DOI
  36. Varakanahalli, 2017, Secondary prophylaxis of hepatic encephalopathy in cirrhosis: a double blind randomized controlled trial of L-ornithine L-aspartate vs placebo, Journal of Clinical and Experimental Hepatology, 7, S60, 10.1016/j.jceh.2017.05.115 · DOI
  37. Zhou, 2013, Ornithine aspartate and naloxone combined therapy for hepatic encephalopathy affects cognitive function, prognosis, and neuropeptide levels, Chinese Journal of Hepatology, 21, 385
  38. Abdo-Francis, 2010, Decreased hospital stay with the use of L-ornithine L- aspartate (LOLA) in patients with hepatic encephalopathy, Revista de Gastroenterología de México, 2, 135
  39. Acharya, 2009, Efficacy of L-ornithine L-aspartate in acute liver failure: a double-blind, randomized, placebo-controlled study, Gastroenterology, 136, 2159, 10.1053/j.gastro.2009.02.050 · DOI · Paper page
  40. Aidrus, 2015, Therapeutic efficacy of L-ornithine L-aspartate in patients with hepatic encephalopathy, Pakistan Journal of Neurological Sciences, 10, 37
  41. Badea M Gavrilescu O Dranga M Mihai C Prelipcean CC Lactulose alone versus lactulose and L-ornithine L-aspartate for the prophylaxis of hepatic encephalopathy in acute variceal bleeding: a prospective case control study Falk Symposium 199 2015 18
  42. Delcker, 2002, Proton MR spectroscopy of neurometabolites in hepatic encephalopathy during L-ornithine-L-aspartate treatment - results of a pilot study, Metabolic Brain Disease, 17, 103, 10.1023/A:1015468112686 · DOI
  43. Grover VP McPhail MJ Wylezinska M Crossey MM Fitzpatrick JA Southern L A longitudinal study of patients with cirrhosis treated with L-ornithine L-aspartate, examined with magnetization transfer, diffusion-weighted imaging and magnetic resonance spectroscopy Metabolic Brain Disease 2017 77 86 · DOI
  44. Lim, 2010, Oral L-ornithine-L-aspartate is safe and effective in patients with intractable hepatic encephalopathy - the NZ liver transplant unit experience, Hepatology International, 4, 258
  45. McPhail, 2013, Modulation of neural activation following treatment of hepatic encephalopathy, Neurology, 80, 1041, 10.1212/WNL.0b013e31828726e1 · DOI
  46. Müting, 1980, Controlled study of the effect of an orally administered ammonia lowering amino acid (ornithine-aspartate) on liver and pancreas function in liver cirrhosis patients, Therapiewoche, 30, 5590
  47. Reikowski, 1982, Controlled study evaluating the effect of high dose oral ornithineaspartate on hepatic encephalopathy in patients with cirrhosis with or without surgical shunts
  48. Ndraha, 2010, The efficacy of L-ornithine L-aspartate granules and normal protein diet in minimal hepatic encephalopathy with malnutrition, Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy, 11, 11
  49. Ong, 2011, Oral L-ornithine-L-aspartate improves health-related quality of life in cirrhotic patients with hepatic encephalopathy: an open-label, prospective, multicentre observational study, Clinical Drug Investigation, 31, 213, 10.2165/11586700-000000000-00000 · DOI
  50. Popa I Badea M Gavrilescu O Dranga M Chiosa AM Didita A Normix alone vs. normix + L-ornithine L-aspartate for the treatment of patients with minimal hepatic encephalopathy Falk Symposium 199 2015 69
  51. Rees, 2000, Effect of L-ornithine-L-aspartate on patients with and without TIPS undergoing glutamine challenge: a double blind, placebo controlled trial, Gut, 47, 571, 10.1136/gut.47.4.571 · DOI
  52. Rees, 1997, The effect of L-ornithine L-aspartate on TIPS patients undergoing glutamine challenge?, 64, 459
  53. Reikowski, 1982, Controlled study evaluating the effect of high dose ornithin-aspartate on hepatic encephalopathy in cirrhosis with or without surgical shunts
  54. Staedt, 1993, Effects of ornithine aspartate on plasma ammonia and plasma amino acids in patients with cirrhosis. A double-blind, randomized study using a four-fold crossover design, Journal of Hepatology, 19, 424, 10.1016/S0168-8278(05)80553-7 · DOI
  55. Tenda, 2013, Effect of BCAA and LOLA combination as late evening snacks on nutritional status and minimal hepatic encephalopathy in cirrhosis [abstract], Hepatology Research, 7, 2185
  56. Tenda, 2012, The effect of branched chain amino acids and L-ornithine L-aspartate combination as the late evening snacks on nutritional status and minimal hepatic encephalopathy in liver cirrhosis, Indonesian Journal of Gastroenterology, Hepatology and Digestive Endoscopy, 13, 151
  57. Tiller, 2016, Motor deficit of hand and arm movements in manifest hepatic encephalopathy before and after therapy with L-ornithin-L-aspartat [abstract], Gastroenterology, 150, S1118, 10.1016/S0016-5085(16)33773-8 · DOI
  58. Atluri, 2011, Pathogenesis, diagnosis, and treatment of hepatic encephalopathy, Journal of Clinical and Experimental Hepatology, 1, 77, 10.1016/S0973-6883(11)60126-6 · DOI
  59. Bai, 2013, L-ornithine-L-aspartate for hepatic encephalopathy in patients with cirrhosis: a meta-analysis of randomized controlled trials, Journal of Gastroenterology and Hepatology, 28, 783, 10.1111/jgh.12142 · DOI
  60. Bajaj, 2008, Inhibitory control test for the diagnosis of minimal hepatic encephalopathy, Gastroenterology, 135, 1591, 10.1053/j.gastro.2008.07.021 · DOI
  61. Bajaj, 2009, Spectrum of neurocognitive impairment in cirrhosis: implications for the assessment of hepatic encephalopathy, Hepatology (Baltimore, Md.), 50, 2014, 10.1002/hep.23216 · DOI
  62. Bajaj, 2010, Persistence of cognitive impairment after resolution of overt hepatic encephalopathy, Gastroenterology, 138, 2332, 10.1053/j.gastro.2010.02.015 · DOI
  63. Bajaj, 2011, Review article: the design of clinical trials in hepatic encephalopathy - an International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) consensus statement, Alimentary Pharmacology & Therapeutics, 33, 739, 10.1111/j.1365-2036.2011.04590.x · DOI
  64. Bajaj, 2011, The multi-dimensional burden of cirrhosis and hepatic encephalopathy on patients and caregivers, American Journal of Gastroenterology, 106, 1646, 10.1038/ajg.2011.157 · DOI
  65. Bass, 2010, Rifaximin treatment in hepatic encephalopathy, New England Journal of Medicine, 362, 1071, 10.1056/NEJMoa0907893 · DOI · Paper page
  66. Blanco Vela, 2011, Determination of ammonia concentrations in cirrhosis patients - still confusing after all these years?, Annals of Hepatology, 10, S60, 10.1016/S1665-2681(19)31609-6 · DOI
  67. Blanco Vela, 2011, Efficacy of oral L-ornithine L-aspartate in cirrhotic patients with hyperammonemic hepatic encephalopathy, Annals of Hepatology, 10, S55, 10.1016/S1665-2681(19)31608-4 · DOI
  68. Bustamante, 1999, Prognostic significance of hepatic encephalopathy in patients with cirrhosis, Journal of Hepatology, 30, 890, 10.1016/S0168-8278(99)80144-5 · DOI
  69. Butterworth, 2014, Hepatic encephalopathy in alcoholic cirrhosis, Handbook of Clinical Neurology, 125, 589, 10.1016/B978-0-444-62619-6.00034-3 · DOI
  70. Butterworth, 2018, Efficacy of L-ornithine L-aspartate for minimal hepatic encephalopathy in cirrhosis: A systematic reviewand meta-analysis of randomised controlled trials, Journal of Hepatology, 68, S714, 10.1016/S0168-8278(18)31688-X · DOI
  71. Cadranel, 2001, Focal neurological signs in hepatic encephalopathy in cirrhotic patients: an underestimated entity?, American Journal of Gastroenterology, 96, 515, 10.1111/j.1572-0241.2001.03552.x · DOI
  72. Chu, 1997, Evoked potentials in liver diseases, Journal of Gastroenterology and Hepatology, 12, S288, 10.1111/j.1440-1746.1997.tb00512.x · DOI
  73. Conn, 1977, Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. A double blind controlled trial, Gastroenterology, 72, 573, 10.1016/S0016-5085(77)80135-2 · DOI
  74. D'Amico, 1986, Survival and prognostic indicators in compensated and decompensated cirrhosis, Digestive Diseases and Sciences, 31, 468, 10.1007/BF01320309 · DOI
  75. D'Amico, 2006, Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies, Journal of Hepatology, 44, 217, 10.1016/j.jhep.2005.10.013 · DOI · Paper page
  76. Jongh, 1992, Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver, Gastroenterology, 103, 1630, 10.1016/0016-5085(92)91188-A · DOI
  77. Delcker, 2000, L-ornithine-L-aspartine vs placebo in the treatment of hepatitis encephalopathy: meta-analysis of randomised placebo-controlled trials using individual data, Hepatology (Baltimore, Md.), 32, 310A
  78. Dhiman, 1995, Figure connection test: a universal test for assessment of mental state, Journal of Gastroenterology and Hepatology, 10, 14, 10.1111/j.1440-1746.1995.tb01041.x · DOI
  79. American Association for the Study of Liver Diseases, 2014, Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases, Journal of Hepatology, 61, 642, 10.1016/j.jhep.2014.05.042 · DOI
  80. Vilstrup, 2014, Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver, Hepatology (Baltimore, Md.), 60, 715, 10.1002/hep.27210 · DOI
  81. Ferenci, 2002, Hepatic encephalopathy - definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998, Hepatology (Baltimore, Md.), 35, 716, 10.1053/jhep.2002.31250 · DOI
  82. Gebhardt, 1997, Treatment of cirrhotic rats with L-ornithine-L-aspartate enhances urea synthesis and lowers serum ammonia levels, Journal of Pharmacology and Experimental Therapeutics, 283, 1, 10.1016/S0022-3565(24)37027-2 · DOI
  83. Gluud C Nikolova D Klingenberg SL Cochrane Hepato-Biliary Group About Cochrane (Cochrane Review Groups (CRGs)) 2017 Issue 6. Art. No.: LIVER
  84. Groeneweg, 1998, Subclinical hepatic encephalopathy impairs daily functioning, Hepatology (Baltimore, Md.), 28, 45, 10.1002/hep.510280108 · DOI
  85. Guérit, 2009, Neurophysiological investigations of hepatic encephalopathy: ISHEN practice guidelines, Liver International, 29, 789, 10.1111/j.1478-3231.2009.02030.x · DOI
  86. Haussinger, 2000, Hepatic encephalopathy in chronic liver disease: a clinical manifestation of astrocyte swelling and low-grade cerebral edema?, Journal of Hepatology, 32, 1035, 10.1016/S0168-8278(00)80110-5 · DOI
  87. Higgins, 2008, Imputation methods for missing outcome data in meta-analysis of clinical trials, Clinical Trials, 5, 225, 10.1177/1740774508091600 · DOI
  88. International Conference on Harmonisation Expert Working Group, 1997, International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline. Guideline for Good Clinical Practice CFR & ICH Guidelines, 1
  89. Jackson, 2016, New spectral thresholds improve the utility of the electroencephalogram for the diagnosis of hepatic encephalopathy, Clinical Neurophysiology, 127, 2933, 10.1016/j.clinph.2016.03.027 · DOI
  90. Jepsen, 2010, The clinical course of alcoholic liver cirrhosis: a Danish population-based cohort study, Hepatology (Baltimore, Md.), 51, 1675, 10.1002/hep.23500 · DOI
  91. Jiang, 2009, L-ornithine-L-aspartate in the management of hepatic encephalopathy: a meta-analysis, Journal of Gastroenterology and Hepatology, 24, 9, 10.1111/j.1440-1746.2008.05582.x · DOI
  92. Kircheis, 2002, Critical flicker frequency for quantification of low-grade hepatic encephalopathy, Hepatology (Baltimore, Md.), 35, 357, 10.1053/jhep.2002.30957 · DOI
  93. Kircheis, 2007, Assessment of low-grade hepatic encephalopathy: a critical appraisal, Journal of Hepatology, 47, 642, 10.1016/j.jhep.2007.05.019 · DOI
  94. Kircheis, 2009, Hepatic encephalopathy and fitness to drive, Gastroenterology, 137, 1706, 10.1053/j.gastro.2009.08.003 · DOI
  95. Lauridsen, 2011, Critical flicker frequency and continuous reaction times for the diagnosis of minimal hepatic encephalopathy: a comparative study of 154 patients with liver disease, Metabolic Brain Disease, 26, 135, 10.1007/s11011-011-9242-1 · DOI
  96. Lockwood, 2004, Blood ammonia levels and hepatic encephalopathy, Metabolic Brain Disease, 19, 345, 10.1023/B:MEBR.0000043980.74574.eb · DOI
  97. Montagnese, 2004, Methods for diagnosing hepatic encephalopathy in patients with cirrhosis: a multidimensional approach, Metabolic Brain Disease, 19, 281, 10.1023/B:MEBR.0000043977.11113.2a · DOI
  98. Neff, 2010, Pharmacoeconomics of hepatic encephalopathy, Pharmacotherapy, 5 Pt 2, 28S, 10.1592/phco.30.pt2.28S · DOI
  99. O'Carroll, 1991, Regional cerebral blood flow and cognitive function in patients with chronic liver disease, Lancet, 337, 1250, 10.1016/0140-6736(91)92920-W · DOI
  100. Olesen, 2016, Electroencephalogram variability in patients with cirrhosis associates with the presence and severity of hepatic encephalopathy, Journal of Hepatology, 65, 517, 10.1016/j.jhep.2016.05.004 · DOI
  101. Parsons-Smith, 1957, The electroencephalograph in liver disease, Lancet, 273, 867, 10.1016/S0140-6736(57)90005-3 · DOI
  102. Perez Hernandez, 2011, Critical analysis of studies evaluating the efficacy of infusion of L-ornithine L-aspartate in clinical hepatic encephalopathy in patients with liver failure, Annals of Hepatology, 10, S66, 10.1016/S1665-2681(19)31610-2 · DOI
  103. Poordad, 2007, Review article: the burden of hepatic encephalopathy, Alimentary Pharmacology & Therapeutics, 25, 3, 10.1111/j.1746-6342.2006.03215.x · DOI
  104. Randolph, 2009, Neuropsychological assessment of hepatic encephalopathy: ISHEN practice guidelines, Liver International, 29, 629, 10.1111/j.1478-3231.2009.02009.x · DOI
  105. Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2014
  106. Roman, 2011, Minimal hepatic encephalopathy is associated with falls, American Journal of Gastroenterology, 106, 476, 10.1038/ajg.2010.413 · DOI
  107. Rose, 1998, L-ornithine-L-aspartate in experimental portal-systemic encephalopathy: therapeutic efficacy and mechanism of action, Metabolic Brain Disease, 13, 147, 10.1023/A:1020613314572 · DOI
  108. Rose, 1999, L-ornithine-L-aspartate lowers plasma and cerebrospinal fluid ammonia and prevents brain edema in rats with acute liver failure, Hepatology (Baltimore, Md.), 30, 636, 10.1002/hep.510300311 · DOI
  109. Royle, 2003, Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches, International Journal of Technology Assessment in Health Care, 19, 591, 10.1017/S0266462303000552 · DOI · Paper page
  110. Saunders, 1981, A 20-year prospective study of cirrhosis, British Medical Journal (Clinical Research Ed.), 282, 263, 10.1136/bmj.282.6260.263 · DOI
  111. Schomerus, 1981, Latent portasystemic encephalopathy. I. Nature of cerebral functional defects and their effect on fitness to drive, Digestive Diseases and Sciences, 26, 622, 10.1007/BF01367675 · DOI
  112. Schomerus, 1998, Neuropsychological aspects of portal-systemic encephalopathy, Metabolic Brain Disease, 13, 361, 10.1023/A:1020645110880 · DOI
  113. Sharma, 2010, Predictors of non response to lactulose in patients with cirrhosis and hepatic encephalopathy, European Journal of Gastroenterology & Hepatology, 22, 526, 10.1097/MEG.0b013e3283341b7d · DOI
  114. Soarez, 2009, A critical analysis of studies assessing L-ornithine-L-aspartate (LOLA) in hepatic encephalopathy treatment, Arquivos de Gastroenterologia, 46, 241, 10.1590/S0004-28032009000300019 · DOI
  115. Sotil, 2009, Impact of preoperative overt hepatic encephalopathy on neurocognitive function after liver transplantation, Liver Transplantation, 15, 184, 10.1002/lt.21593 · DOI
  116. Stepanova, 2012, In hospital mortality and economic burden associated with hepatic encephalopathy in the United States from 2005 to 2009, Clinical Gastroenterology and Hepatology, 10, 1034, 10.1016/j.cgh.2012.05.016 · DOI
  117. Stewart, 2007, Hepatic encephalopathy as a predictor of survival in patients with end-stage liver disease, Liver Transplantation, 13, 1366, 10.1002/lt.21129 · DOI
  118. Taylor-Robinson, 1994, Regional variations in cerebral proton spectroscopy in patients with chronic hepatic encephalopathy, Metabolic Brain Disease, 9, 347, 10.1007/BF02098881 · DOI
  119. Teasdale, 1974, Assessment of coma and impaired consciousness. A practical scale, Lancet, 2, 81, 10.1016/S0140-6736(74)91639-0 · DOI · Paper page
  120. Victor, 1965, The acquired (non-Wilsonian) type of chronic hepatocerebral degeneration, Medicine, 44, 345, 10.1097/00005792-196509000-00001 · DOI
  121. Weissenborn, 1998, Diagnosis of encephalopathy, Digestion, 59, 22, 10.1159/000051415 · DOI
  122. Weissenborn, 2001, Neuropsychological characterization of hepatic encephalopathy, Journal of Hepatology, 34, 768, 10.1016/S0168-8278(01)00026-5 · DOI
  123. Wetterslev, 2017, Trial Sequential Analysis in systematic reviews with meta-analysis, BMC Medical Research Methodology, 17, 39, 10.1186/s12874-017-0315-7 · DOI
  124. Wright, 2011, Interorgan ammonia metabolism in liver failure: the basis of current and future therapies, Liver International, 31, 163, 10.1111/j.1478-3231.2010.02302.x · DOI
  125. Zacharias, 2016, Ammonia scavenging agents for people with cirrhosis and hepatic encephalopathy, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD012334 · DOI
  126. Zipprich, 2012, Prognostic indicators of survival in patients with compensated and decompensated cirrhosis, Liver International, 32, 1407, 10.1111/j.1478-3231.2012.02830.x · DOI
  127. Stokes, 2016, L-ornithine L-aspartate for people with cirrhosis and hepatic encephalopathy, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD012410 · DOI
  128. Yuan, 2008, L-ornithine-L-aspartate for hepatic encephalopathy, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD007344 · DOI

Cited by

Sorted by citations

See all 54

Metadata

Authors
Goh, E. T., Stokes, C. S., Sidhu, S. S., Vilstrup, H., Gluud, L. L., & Morgan, M. Y.
Affiliations
  • Division of Medicine, Royal Free Campus, University College London; UCL Institute for Liver & Digestive Health; Rowland Hill Street Hampstead London UK NW3 2PF
  • Saarland University Medical Centre; Department of Medicine II; Kirrberger Str. 100 Homburg/Saar Germany 66421
  • Dayanand Medical College & Hospital; Department of Gastroenterology; Tagore Nagar, Civil Lines Ludhiana Punjab India 141001
  • Aarhus University Hospital; Department of Hepatology and Gastroenterology; Nørrebrogade 44 Aarhus 8200 N Denmark
  • Copenhagen University Hospital Hvidovre; Gastrounit, Medical Division; Kettegaards Alle 30 Hvidovre Denmark 2650
Venue
Cochrane Database of Systematic Reviews
Publisher
Wiley
Published
2018-05-15
Volume
2019
Issue
6
ISSN
1465-1858
DOI
10.1002/14651858.cd012410.pub2
Cited by
54
References
5
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review